viernes, 10 de marzo de 2017
Targeted Immunotherapy for Pancreatic Cancer
View Clinical Trial NCT02810418 - National Cancer Institute
This phase I/II trial is for patients with advanced pancreatic cancer. The goal is to determine the best dose of immunotherapy drug LMB-100 and see how well it works when given with nab-paclitaxel, a standard chemotherapy used for pancreatic cancer.